Evidence map›Paper›PMID 38554167›Full record

ArticleCancer immunology, immunotherapy : CII2024

Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth.

Andrew N Wilkinson, Rui Chen, Elaina Coleborn, Trent Neilson, Khang Le, Chintan Bhavsar, Yue Wang, Sharat Atluri, Gowri Irgam, Kiefer Wong and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Andrew N WilkinsonSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD, 4072, Australia.
Rui ChenSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD, 4072, Australia.
Elaina ColebornSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD, 4072, Australia.
Trent NeilsonSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD, 4072, Australia.
Khang LeSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD, 4072, Australia.
Chintan BhavsarSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD, 4072, Australia.
Yue WangDepartment of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
Sharat AtluriSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD, 4072, Australia.
Gowri IrgamSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD, 4072, Australia.
Kiefer WongSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD, 4072, Australia.
Da YangDepartment of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
Raymond SteptoeFrazer Institute, University of Queensland, Brisbane, QLD, 4102, Australia.
Sherry Y WuSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD, 4072, Australia. sherry.wu@uq.edu.au.ORCID https://orcid.org/0000-0002-6051-4252
The University of Queensland · AUUniversity of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunotherapy has seen significant success in the last decade for cancer management by enhancing endogenous cancer immunity. However, immunotherapies developed thus far have seen limited success in the majority of high-grade serous carcinoma (HGSC) ovarian cancer patients. This is largely due to the highly immunosuppressive tumour microenvironment of HGSC and late-stage identification. Thus, novel treatment interventions are needed to overcome this immunosuppression and complement existing immunotherapies. Here, we have identified through analysis of > 600 human HGSC tumours a critical role for Let-7i in modulating the tumoural immune network. Tumoural expression of Let-7i had high positive correlation with anti-cancer immune signatures in HGSC patients. Confirming this role, enforced Let-7i expression in murine HGSC tumours resulted in a significant decrease in tumour burden with a significant increase in tumour T cell numbers in tumours. In concert with the improved tumoural immunity, Let-7i treatment also significantly increased CD86 expression in antigen presenting cells (APCs) in the draining lymph nodes, indicating enhanced APC activity. Collectively, our findings highlight an important role of Let-7i in anti-tumour immunity and its potential use for inducing an anti-tumour effect in HGSC.

Indexed as

MicroRNAsOvarian NeoplasmsAnimalsFemaleHumansMiceT-LymphocytesTumor MicroenvironmentMicroRNAsmirnlet7 microRNA, humanCancer immunityLet-7imiRNAOvarian cancer

Identifiers

PMID38554167
PMCPMC10981620
OpenAlexW4393343245

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.